Eight years old is third grade for many children. It’s multiplication tables, playground friendships, after-school snacks and still needing a parent for more things than they would probably admit. Increasingly, it can also be an age when a child with obesity is prescribed a GLP-1 medication.
That can be hard to wrap your head around. Drugs like Wegovy, Saxenda and Zepbound have become so closely associated with adult weight loss that hearing them discussed in connection with an elementary school child can feel jarring. Yet the conversation about weight-loss drugs for children is no longer hypothetical. A new study published in Pediatrics found that GLP-1 prescribing among children ages 8 to 11 with obesity increased 310-fold between 2019 and 2026.
The number certainly got my attention, but it also made me want to know more. How many children are we actually talking about? Why are clinicians prescribing these medications at such young ages? And what is going on with the health of the children who are receiving them?
Those questions matter to me professionally and personally. I’m a family nurse practitioner, and children are part of the patients I care for. I’ve seen kids this age with obesity who already have high blood pressure, elevated cholesterol and other metabolic concerns. I’m also a mother, so I understand the hesitation a parent might have if a clinician brought up a medication like this for their child. I would have questions, too.
Childhood Obesity Can Affect Health Earlier Than We Think
What I’ve seen in practice is also reflected in the pediatric obesity guidelines. The American Academy of Pediatrics identifies hypertension, dyslipidemia, insulin resistance, type 2 diabetes and fatty liver disease among the health risks associated with childhood obesity. Its guidelines call for blood pressure checks at every visit beginning at age 3 for children with overweight or obesity, and clinicians may evaluate children ages 2 through 9 with obesity for lipid abnormalities.
I’ve looked at elevated blood pressures and abnormal lab results in young patients and had to talk with families about health problems showing up much earlier than anyone would like. At that point, obesity isn’t only about a child’s weight or what might happen 20 years from now. You’re dealing with what is happening to that child’s health today.
Prescribing Increased 310-Fold Among Children Ages 8 to 11
The study included more than 3.5 million children ages 8 to 11 with obesity and without diabetes. Researchers examined prescriptions for liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide (Zepbound) between 2019 and June 2026.
The 310-fold increase is dramatic, but it needs context. Across the entire study population, only 0.6% of children received a GLP-1 prescription. The 9.3% figure reported for 2026 refers to prevalent prescribing within that annual cohort, not 9.3% of all 3.5 million children studied.
Another finding deserves attention. Children with obesity-related comorbidities had substantially higher prescribing rates. The researchers noted that the pattern suggests clinicians may be reserving these medications for children with greater cardiometabolic risk.
The study cannot tell us whether each prescription was appropriate or why an individual clinician prescribed it. It also wasn’t an outcomes study, so we can’t use it to say whether these children became healthier because they received a GLP-1. What it does show is that use of these medications in younger children is changing, and quickly.
That shift is happening against a much larger childhood obesity problem. About 1 in 5 U.S. children and adolescents has obesity, according to the CDC. Among children ages 6 to 11, prevalence is approximately 20.7%.
Can Children Under 12 Take GLP-1 Medications for Obesity?
Yes, GLP-1 medications can be prescribed to children younger than 12 for obesity, but that use is currently off-label. The distinction between what clinicians may consider and what the FDA has specifically approved is important.
The American Academy of Pediatrics recognizes obesity as a chronic disease and recommends comprehensive, family-centered treatment. Its 2023 clinical practice guideline states that clinicians may offer children ages 8 through 11 with obesity weight-loss pharmacotherapy, according to medication indications, risks and benefits, as an adjunct to health behavior and lifestyle treatment.
That wording matters. “May offer” is not the same as “should prescribe,” and medication is not intended to replace nutrition, physical activity or behavioral treatment.
GLP-1 medications currently used for obesity are not FDA-approved specifically for obesity treatment in children younger than 12. Prescribing one for that purpose in an 8-, 9-, 10- or 11-year-old would therefore be off-label.
Off-label doesn’t automatically mean inappropriate. It’s common in many areas of medicine, including pediatrics. But it does raise the bar for the clinical conversation. What evidence supports using this medication in this particular child? What are the known risks? What don’t we know yet? What other treatments have been tried or are being used alongside it? And how will the child’s growth, nutrition, development and response to treatment be monitored?
What Does the Research Show About GLP-1s in Younger Children?
The evidence on GLP-1s for children younger than 12 is growing, but it is still limited. We don’t have decades of data in elementary school-aged children, and I don’t think we should pretend that we do. But saying we need more evidence is different from saying there is no evidence.
A randomized clinical trial published in The New England Journal of Medicine studied liraglutide in 82 children ages 6 to younger than 12 with obesity. Both the treatment and placebo groups received lifestyle intervention. After 56 weeks, mean BMI decreased 5.8% in children receiving liraglutide compared with a 1.6% increase among those receiving placebo. Forty-six percent of children receiving liraglutide achieved at least a 5% reduction in BMI, compared with 9% receiving placebo.
Those results are meaningful, but 82 children is still 82 children. Gastrointestinal adverse events were also common, occurring in 80% of children receiving liraglutide compared with 54% receiving placebo. The study was funded by Novo Nordisk.
More recently, Novo Nordisk announced topline results from its Phase 3 STEP Young trial evaluating semaglutide in children ages 6 to younger than 12. The company reported that 40.4% of children receiving semaglutide plus lifestyle intervention were below the obesity threshold after 68 weeks, compared with none receiving placebo plus lifestyle intervention.
Those findings are promising, but there’s an important evidence distinction here. As of this writing, those are manufacturer-announced topline results, not results from a full peer-reviewed publication. I want to see the complete data before drawing broader conclusions.
What Are the Risks of GLP-1s for Children?
There are legitimate questions about using GLP-1 medications in younger children. We need longer-term data on growth and development, nutritional adequacy, adverse effects, duration of therapy and what happens after children stop treatment. We also need larger studies.
Related: Why Patients Stop GLP-1 Medications and How One Nurse Improved Adherence to 92%
As a mother, those questions matter to me. As a clinician, however, I can’t stop the risk-benefit analysis there.
I’ve cared for children with obesity whose blood pressure is already elevated or whose cholesterol is already abnormal. The AAP guidelines reinforce that these health concerns can begin long before adulthood. The guideline cites evidence that elevated blood pressure can be present even among very young children with obesity, including an 8% prevalence among children ages 3 to 5 with obesity in one primary care study.
So when I’m considering any treatment, I have to think about the potential risks of the treatment and the health risks associated with the condition I’m trying to treat. That doesn’t automatically tip the scale toward medication. It means both sides belong on the scale.
Medication Is Only One Part of Comprehensive Obesity Treatment
One concern I hear frequently is that medication allows clinicians or families to bypass nutrition, exercise and behavior change. That’s not how these medications were studied in the pediatric trials, and it isn’t how the AAP guideline describes their use.
Children in the clinical trials received lifestyle intervention alongside medication or placebo. Pharmacotherapy is an adjunct to comprehensive obesity treatment, not a substitute for it.
Pediatric obesity is also more complicated than “eat less and move more.” Family history, medications, sleep, food access, physical activity, social determinants of health and a child’s home environment can all be relevant. Treatment has to make sense for the child and family who actually have to live with it.
There is also a child at the center of all of this. Conversations about obesity and weight-loss medications can affect how children see their bodies and themselves. Whatever treatment is chosen, it should be delivered without shame or stigma and in a way that supports the child’s physical and emotional health.
Access to Pediatric Obesity Treatment Is Not Equal
One finding from the prescribing study shouldn’t get buried beneath the 310-fold headline. Children living in areas with lower social vulnerability had higher GLP-1 prescribing rates than children living in areas with greater social vulnerability.
The study can’t tell us why that difference exists, and we shouldn’t manufacture an explanation the researchers didn’t establish. But it should make us curious.
Who gets referred to pediatric obesity specialists? Whose insurance covers these medications? Which families can make repeated appointments, obtain laboratory testing, navigate prior authorizations and consistently fill prescriptions? And if these medications eventually become an established option for younger children, will the children with the greatest health needs actually have access to them?
Related: Insurance Denials for Brand Name Drugs Rose 67%, Creating New Barriers to Patient Care
A new treatment doesn’t automatically create more equitable healthcare. Sometimes it exposes inequities that were already there.
So, Are 8-Year-Olds Too Young for GLP-1s?
I don’t think there is a responsible one-word answer to that question.
I wouldn’t want an 8-year-old prescribed a GLP-1 simply because their BMI crossed the 95th percentile. I also wouldn’t want medication used because everyone is talking about GLP-1s or because a family is looking for rapid weight loss.
But I don’t believe age alone should prevent a clinician from considering pharmacotherapy for a child whose obesity is already affecting their health. That decision should be based on an appropriate evaluation, the available evidence, the child’s individual risks and benefits and a comprehensive treatment plan.
Healthcare professionals should be cautious. We should ask hard questions about the evidence, long-term safety, development, nutrition and what we still don’t know. We should also be careful not to let our discomfort with treating a young child become a reason to undertreat a chronic disease.
As a family nurse practitioner and a mother, that’s where I land. Eight years old sounds incredibly young when we’re talking about a GLP-1 medication. It also sounds incredibly young when we’re talking about hypertension and elevated cholesterol.
Unfortunately, sometimes we’re talking about both.
